Walk the talk on TRIPS waiver

News Today 18.05.2021

When the pandemic hit the globe, India and South Africa piloted the proposal to waive key provisions of the TRIPS agreement on COVID-19 vaccines, drugs, therapeutics, and related technologies. The core idea is that IPRs such as patents should not become barriers in scaling up production of medical products essential to combat COVID-19. The TRIPS waiver proposal, now backed by the U.S., is essential because it would give immunity to member countries from a legal challenge at the WTO if their domestic IPR laws suspend or do not enforce IP protection on COVID-19 medical products. (Read More)


Be the first to comment

Leave a Reply

Your email address will not be published.